Phase 1 and 3 trials demonstrated improved survival rates, with new treatment strategies for EGFR-mutated NSCLC, HER2+ breast cancer, and small-cell lung cancer. AI innovations, such as the ASCO ...

Keytruda/Welireg and Welireg/Lenvima combinations show improved survival and disease control in kidney cancer, according to new data from ASCO GU. The third and final day of the 2026 American Society ...

Lymphoma highlights from ASCO 2025 are reported by Dr Christopher Flowers from MD Anderson Cancer Center in Houston, Texas. Dr Flowers first reviews a phase 1 study of KITE-363, an anti-CD19/CD20 ...

An exceptional range of practice-changing advancements in metastatic breast cancer across all subtypes were presented at ASCO 2025 and are discussed by Dr Ann Partridge of the Dana-Farber Cancer ...

Each year, the American Society of Clinical Oncology annual meeting brings together the biggest names and brightest minds in cancer research, and this year was no exception. In this episode of "The ...

Drug that stops cancer cells hiding and a breakthrough pill for pancreatic cancer among highlights from Asco conference – but there were also notes of caution ...

ASCO 2026 marked an important transition in oncology. Rather than showcasing isolated advances, the meeting demonstrated how precision medicine, targeted therapies, immunotherapy, individualized ...

Standardized PSADT calculations are crucial for timely prostate cancer treatment, potentially preventing metastasis and reducing treatment costs. Casdatifan shows promise in clear cell RCC, with a 100 ...